Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-270 in Relapsed or Refractory Clear Cell Renal Cell Carcinoma
NCT06480565Phase 1Terminated
- Sponsor
- Adicet Bio
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of ADI-270 in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Adicet Bio. Primary endpoints: Dose Limiting Toxicities at 28 days and Treatment Emergent and Treatment Related Adverse Events at 2 years. Started Dec 2024; status: terminated.
02
Drugs
ADI-270
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06480565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06480565.